AKT1 and pancreatic neoplasm: Although no mutations in PI3K or Akt1 have been reported so far, evidence suggests that the PI3K/Akt pathway is active in pancreatic cancers [12-14], which indicates that the pathway is a putative therapeutic target in such cancers.